Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients
NCT07020533Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2026
- Primary completion
- Feb 2030
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Triplex in cytomegalovirus infection (CMV) (4 arms), sponsored by City of Hope. Primary endpoints: Cytomegalovirus reactivation prompting antiviral therapy and Cytomegalovirus disease. Started Sep 2026; status: recruiting.
02
Drugs
Triplex
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07020533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020533.